Jeffrey Eisele - 27 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Development Officer
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Issuer symbol
APLS
Transactions as of
27 Jan 2023
Transactions value $
-$19,367
Form type
4
Filing time
30 Jan 2023, 15:58:00 UTC
Previous filing
25 Jan 2023
Next filing
31 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Tax liability -$19,366 -367 -0.77% $52.77 47,351 27 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares withheld for tax on a restricted stock unit release.